



Concomitant CIS on TURBT does not impact oncological outcomes in patients treated with neoadjuvant or induction chemotherapy followed by radical cystectomy

N. Vasdev^{1,2,3} · H. Zargar^{4,5,6} · J. P. Noël^{1,2} · R. Veeratterapillay³ · A. S. Fairey^{8,13} · L. S. Mertens⁹ · C. P. Dinney¹⁰ · M. C. Mir^{4,5} · L. M. Krabbe¹¹ · M. S. Cookson¹² · N. E. Jacobsen¹³ · N. M. Gandhi¹⁴ · J. Griffin¹⁵ · J. S. Montgomery¹⁶ · E. Y. Yu¹⁷ · E. Xylinas¹⁸ · N. J. Campain²⁰ · W. Kassouf²¹ · M. A. Dall'Era²² · J. A. Seah²³ · C. E. Ercole^{4,5} · S. Horenblas⁹ · S. S. Sridhar²³ · J. S. McGrath²⁰ · J. Aning^{3,20} · S. F. Shariat^{18,19} · J. L. Wright¹⁷ · T. M. Morgan¹⁶ · T. J. Bivalacqua¹⁴ · S. North²⁴ · D. A. Barocas²⁵ · Y. Lotan¹¹ · P. Grivas¹⁷ · A. J. Stephenson^{4,5} · J. B. Shah¹⁰ · B. W. van Rhijn⁹ · S. Daneshmand⁸ · P. E. Spiess⁷ · J. M. Holzbeierlein¹⁵ · A. Thorpe³ · P. C. Black⁶

Received: 30 March 2018 / Accepted: 28 May 2018 / Published online: 7 June 2018
© Springer-Verlag GmbH Germany, part of Springer Nature 2018

Abstract

Background Cisplatin-based neoadjuvant chemotherapy (NAC) for muscle invasive bladder cancer improves all-cause and cancer specific survival. We aimed to evaluate whether the detection of carcinoma in situ (CIS) at the time of initial transurethral resection of bladder tumor (TURBT) has an oncological impact on the response to NAC prior to radical cystectomy.

Patients and methods Patients were identified retrospectively from 19 centers who received at least three cycles of NAC or induction chemotherapy for cT2-T4aN0-3M0 urothelial carcinoma of the bladder followed by radical cystectomy between 2000 and 2013. The primary and secondary outcomes were pathological response and overall survival, respectively. Multi-variable analysis was performed to determine the independent predictive value of CIS on these outcomes.

Results Of 1213 patients included in the analysis, 21.8% had concomitant CIS. Baseline clinical and pathologic characteristics of the ‘CIS’ versus ‘no-CIS’ groups were similar. The pathological response did not differ between the two arms when response was defined as pT0N0 (17.9% with CIS vs 21.9% without CIS; $p=0.16$) which may indicate that patients with CIS may be less sensitive to NAC or \leq pT1N0 (42.8% with CIS vs 37.8% without CIS; $p=0.15$). On Cox regression model for overall survival for the cN0 cohort, the presence of CIS was not associated with survival (HR 0.86 (95% CI 0.63–1.18; $p=0.35$)). The presence of LVI (HR 1.41, 95% CI 1.01–1.96; $p=0.04$), hydronephrosis (HR 1.63, 95% CI 1.23–2.16; $p=0.001$) and use of chemotherapy other than ddMVAC (HR 0.57, 95% CI 0.34–0.94; $p=0.03$) were associated with shorter overall survival. For the whole cohort, the presence of CIS was also not associated with survival (HR 1.05 (95% CI 0.82–1.35; $p=0.70$)).

Conclusion In this multicenter, real-world cohort, CIS status at TURBT did not affect pathologic response to neoadjuvant or induction chemotherapy. This study is limited by its retrospective nature as well as variability in chemotherapy regimens and surveillance regimens.

Keywords Neoadjuvant chemotherapy · Carcinoma insitu · Bladder cancer · Radical cystectomy

Introduction

Cisplatin-based neoadjuvant chemotherapy (NAC), followed by radical cystectomy (RC) and bilateral pelvic lymph node dissection is considered the standard of care for patients with muscle invasive bladder cancer (MIBC) who are eligible to receive this multimodal therapy. This approach has been shown to improve all-cause and cancer-specific mortality compared to RC alone [1, 2]. The pathologic response,

✉ N. Vasdev
nikhil.vasdev@nhs.net

Extended author information available on the last page of the article

defined as either no residual carcinoma (pT0N0) or no residual MIBC (\leq pT1N0), is considered a surrogate end point for overall survival [3]. Patients with residual MIBC have a high risk of recurrence and subsequent death from bladder cancer [2].

In current clinical practice, it is sometimes suggested that NAC may have less effect on CIS, which could lead patients with concomitant CIS to have a higher rate of residual disease after NAC [14, 15]. There is little evidence in the literature regarding the oncological response of patients with CIS to NAC. We hypothesized that there is no difference in outcome in patients diagnosed with CIS on initial TURBT who subsequently receive NAC prior to RC. We tested this hypothesis in a large international consortium.

Patients and methods

Study population

From 2000 to 2013, patients with MIBC (cT2-T4aN0-3M0) who were managed with pre-operative systemic chemotherapy followed by RC were retrospectively identified at 19 centers across Europe, Canada and the USA. These centers collectively agreed to share data and this was approved by the respective Institutional Review Boards at each center. The term neoadjuvant chemotherapy (NAC) is conventionally used only for patients with cN0M0 bladder cancer. Here, we also included patients receiving induction chemotherapy for cN1-3M0 disease under the term NAC.

The study population was divided into patients with and without CIS at TURBT. All patients had urothelial carcinoma of the bladder. Mixed histology with squamous and/or glandular differentiation was allowed, but no other variant histology. All patients received at least three cycles of NAC prior to RC.

Information regarding demographics, clinical staging, chemotherapy regimen and other treatment parameters was obtained. Additionally, the pathological outcome after cystectomy was retrieved. All centers used the American Joint Committee on Cancer (AJCC) criteria for pathologic assessment, but there was no central review.

Statistical analysis

Clinical and pathologic data were compared between groups. For variables with non-normal distribution, data were presented as median and interquartile range (IQR), and the respective groups were compared using the Mann–Whitney U test. Categorical variables were compared using the χ^2 test. Multivariable logistic regression analysis of selected variables (age, cT stage, gender and type of chemotherapy regimen) was used to define factors predicting pCR

(pathological complete response) and pPR (pathological partial response). For comparison of adjusted pathologic response rates, the odds ratio (OR) was reported, and the 95% confidence interval (CI) was calculated with bootstrapping. The multivariable Cox proportional hazards regression model for survival was used to assess hazard ratios (HRs) for variables of interest selected based on univariable analysis as well as clinical relevance (gender, type of chemotherapy regimen, surgical margin, extent of lymph node dissection and presence of pPR). Significance was set at p value < 0.05 . Analyses were performed using SPSS v.21 software (IBM SPSS Statistics; IBM Corp, Armonk, NY, USA). The primary outcome was pathologic response defined as either pT0N0 or \leq pT1N0 in RC specimens. Multivariate analysis was performed to identify factors predictive of either outcome. Multivariable binary regression models were created, first including all cN stages and then only for patients with cN0 disease. The same was also repeated only in patients who received cisplatin-based chemotherapy. A multivariable Cox regression model for overall survival was also generated. Significance was set at p value < 0.05 .

Results

After applying our selection criteria from the total of 1865 patients, 1253 met our criteria. The presence of CIS was not annotated in 40 patients and they were excluded from the analysis. Overall, 1213 patients met criteria, including 823 patients who were cN0, 117 cNx and 273 cN1-3. Concomitant CIS was reported in 21.8% of the patients. Table 1 shows the clinical and pathological features in both the “CIS” and “no-CIS” cohorts. The “no-CIS” patients had higher baseline risk with respect to cT stage, cN stage and hydronephrosis, whereas the rate of lymphovascular invasion (LVI) was higher in the “CIS” patients.

The NAC regimens employed were gemcitabine–cisplatin (GC) in 608 (50.1%), methotrexate–vinblastine–adriamycin–cisplatin (MVAC) or dose-dense MVAC in 401 (33.1%) and other in 196 (16.2%) (Table 2). The NAC regimen was not specified for the remaining patients (0.6%). There was no difference between groups with respect to NAC regimens. The time from NAC to cystectomy was significantly longer in patients with CIS (17 weeks) versus those without CIS (16 weeks; $p = 0.006$). The median follow-up was 1.6 years (range 0.5–3.5 years).

The pathological response for all patients regardless of cN status showed no significant difference according to CIS status (Table 2). However, if only cN0 patients were considered, the downstaging to \leq pT1N0 occurred more frequently in the CIS group (53.0%) than in the non-CIS group (41.7%; $p = 0.007$). Downstaging to pT0N0 did not differ according to CIS status.

Table 1 Baseline demographic and clinicopathological findings at initial TURBT

	CIS 265	No CIS 948	<i>p</i>
Age, median (IQR) years	64 (57,71)	64 (57, 71)	0.75
Male gender, <i>N</i> (%)	199 (75.1)	722 (76.1)	0.91
Never smoked, <i>N</i> (%)	65 (28.1)	246 (30.3)	0.89
Clinical T stage, <i>N</i> (%)			0.06
T2	161 (60.8)	499 (52.6)	
T3	72 (27.2)	309 (32.6)	
T4a	32 (12.1)	140 (14.8)	
Clinical N stage, <i>N</i> (%)			0.05
N0	188 (70.9)	635 (67.0)	
N+	46 (17.4)	227 (23.9)	
Nx	31 (11.7)	86 (9.1)	
Hydronephrosis, <i>N</i> (%)			0.03
Present	63 (23.8)	305 (32.2)	
Absent	139 (52.5)	450 (47.5)	
Status unknown	63 (23.8)	193 (20.4)	
LVI, <i>N</i> (%)			0.04
Yes	59 (22.3)	163 (17.2)	
No	99 (37.4)	432 (45.6)	
Unavailable data	107(40.4)	353 (37.2)	
Primary pathology TURBT, <i>N</i> (%)			0.94
Urothelial cancer	236 (89.1)	839 (88.5)	
Urothelial cancer with squamous differentiation	22 (8.3)	85 (9.0)	
Urothelial cancer with glandular differentiation	7 (2.6)	24 (2.5)	

IQR interquartile range, *LVI* lymphovascular invasion, *TURBT* transurethral resection of bladder tumour

Table 3 summarizes the multivariable analysis assessing potential risk factors for pathologic downstaging in all patients (cN0-3). cN1-3 status was an independent predictor of lower pT0N0 (compared to cN0; OR 0.48, 95% CI 0.32–0.72; $p < 0.001$) and \leq pT1N0 rates (compared to cN0; 0.44, 95% CI 0.31–0.61; $p < 0.001$). Table 4 summarizes the multivariable analysis assessing potential risk factors for pathologic down-staging for patients with N0 disease.

On Cox regression model for overall survival for the cN0 cohort using clinicopathological data (Table 5), the presence of CIS was not associated with survival (HR 0.87 (95% CI 0.64–1.89; $p = 0.38$). The presence of LVI (HR 1.44, 95% CI 1.04–2.00; $p = 0.03$), hydronephrosis (HR 1.58, 95% CI 1.18–2.11; $p = 0.002$) and use of a chemotherapy regimen other than ddMVAC (HR 0.58, 95% CI 0.35–0.96; $p = 0.03$) were associated with worse survival outcomes.

Assessing overall survival for the entire cohort (Table 6), cN+ status, the presence of hydronephrosis and the use of a chemotherapy regimen other than ddMVAC predicted worse overall survival. The presence of CIS was not associated with overall survival (HR 1.06 (95% CI 0.83–1.36; $p = 0.65$). When the same analyses were performed for either cN0-3 or cN0 patients who received only cisplatin-based chemotherapy, the results did not change significantly (data not shown).

Discussion

Risk stratification to guide optimal management of patients with MIBC is limited to that obtained from bimanual examination, imaging and pathologic data from TURBT samples. The use of cisplatin-based NAC offers an overall survival advantage, but some patients do not respond and likely experience only adverse effects with no clinical benefit. It is therefore important to identify patients who are less likely to respond and/or more likely to progress during NAC [1–3]. Potential clinical factors that may be associated with lower response to NAC include tumor location at the bladder neck, presence of hydronephrosis and variant histology such as sarcomatoid, small cell, plasmacytoid or micropapillary carcinoma [4]. Furthermore, research has revealed that genomic markers such as DNA damage repair gene (ERCC2, Rb1, FANCC, ATM) mutations, ErbB2 alterations, molecular subtyping based on gene expression and the Co-expression Extrapolation (COXEN) model for analysis of gene expression signatures may predict response to cisplatin-based NAC [5–10]. Ongoing clinical trials are evaluating the clinical utility of such molecular biomarkers (e.g., NCT02177695, NCT02710734) [4, 10].

Table 2 Chemotherapy regimens and final pathological results

	CIS N (%)	No CIS N (%)	<i>p</i> value
Number of patients	265 (21.8)	948 (72.2)	
Chemo regimen			0.18
ddMVAC, <i>N</i> (%)	50 (18.9)	211 (22.3)	
MVAC, <i>N</i> (%)	31 (11.7)	109 (11.5)	
GC, <i>N</i> (%)	133 (50.2)	475 (50.1)	
Other, <i>N</i> (%)	49 (18.5)	147 (15.5)	
Unavailable data	2 (0.8)	6 (0.6)	
Number of Cycles			
3 cycles, <i>N</i> (%)	122 (46.0)	371 (39.1)	0.07
4 cycles, <i>N</i> (%)	111 (41.9)	494 (52.2)	
> 4 cycles, <i>N</i> (%)	32 (12.1)	83 (8.8)	
Time between TURBT and NAC**, median (IQR) weeks	6 (2.8)	5 (2.10)	0.13
Duration of NAC, median (IQR) weeks	9 (6.12)	9 (5.12)	0.35
Time between NAC and cystectomy, median (IQR) weeks	17 (14. 24)	16 (12.21)	0.006
Pathological outcome			
All cNstage, <i>N</i> (%)	46 (17.9)	204 (21.9)	0.16
pT0N0	110 (42.8)	352 (37.8)	0.15
≤pT1N0			
cN0, <i>N</i> (%)	42 (23.0)	152 (24.5)	0.67
pT0N0	97 (53.0)	259 (41.7)	0.007
≤pT1N0			
CIS on final pathology, <i>N</i> (%)	116 (43.8)	248 (26.2)	<0.001
Number of nodes removed, median (IQR)	18 (12–27)	18 (10–27)	0.58
Number of positive nodes, median (range)	0 (0–21)	0 (0–50)	0.22
Positive surgical margin, <i>N</i> (%)	22 (8.4)	102 (10.9)	0.31
Follow up time, median years	1.2 (0.5,2.3)	1.4 (0.5,2.9)	0.11

** Time between TURBT and start of NAC

Table 3 Predictors of pT0N0 and ≤ypT1N0 for the entire cohort (pT2–4, N0–3; *n* = 1213)

Variables	≤ypT1N0 OR (95%CI)	<i>p</i>	ypT0N0 OR (95%CI)	<i>p</i>
Gender*				
Female	1		1	
Male	0.75 (0.66, 1.04)	0.08	0.77 (0.38, 1.55)	0.46
cT stage				
cT2	1		1	
cT3–4	0.83 (0.64, 1.08)	0.17	0.85 (0.63, 1.16)	0.31
NAC regimen				
MVAC	1		1	
ddMVAC	1.49 (0.93, 2.38)	0.09	1.70 (0.95, 3.03)	0.07
GC	1.39 (0.90, 2.15)	0.13	1.46 (0.84, 2.51)	0.17
Other	1.19 (0.72, 1.97)	0.49	1.54 (0.83, 2.84)	0.17
cN stage				
N0	1		1	
N+	0.44 (0.31, 0.61)	<0.001	0.48 (0.32, 0.72)	<0.001
Nx	0.74 (0.47, 1.16)	0.19	0.66 (0.37, 1.15)	0.14
CIS				
No	1		1	
Yes	0.93 (0.67, 1.27)	0.64	0.66 (0.45, 0.98)	0.04

* Addition of this variable did not alter the performance of the other variables and this was not included in the final model

Table 4 Predictors of pT0N0 and \leq ypT1N0 for cT2-4, N0 patients ($n = 823$)

Variables	\leq ypT1N0 OR (95%CI)	<i>p</i>	ypT0N0 OR (95%CI)	<i>p</i>
Gender*				
Female	1		1	
Male	0.73 (0.49, 1.09)	0.13	0.88 (0.56, 1.38)	0.58
cT stage				
cT2	1		1	
cT3-4	0.66 (0.48, 0.91)	0.01	0.71 (0.49, 1.03)	0.07
NAC regimen				
MVAC	1		1	
ddMVAC	1.32 (0.72, 2.44)	0.36	1.23 (0.62, 2.46)	0.54
GC	1.17 (0.66, 2.08)	0.56	1.03 (0.53, 1.98)	0.93
Other	0.88 (0.45, 1.74)	0.72	0.97 (0.45, 2.11)	0.94
CIS				
No	1		1	
Yes	1.18 (0.81, 1.72)	0.38	0.79 (0.51, 1.23)	0.30

* Addition of this variable did not alter the performance of the other variables and this was not included in the final model

Table 5 Cox regression model for OS for cT2-4,N0 cohort using pre-cystectomy data

Variables	OS HR (95% CI)	<i>p</i>
Age	1.00 (0.99, 1.01)	0.40
cT stage		
cT2	1	
cT3-4	1.14 (0.88, 1.48)	0.31
NAC regimen		
MVAC	1	
ddMVAC	0.58 (0.35, 0.96)	0.03
GC	1.00 (0.65, 1.55)	0.98
Other	1.11 (0.68, 1.80)	0.68
LVI		
No	1	
Yes	1.44 (1.04, 2.00)	0.03
Unknown	1.13 (0.83, 1.54)	0.44
Hydronephrosis		
No	1	
Yes	1.58 (1.18, 2.11)	0.002
Unknown	1.33 (0.93, 1.92)	0.11
CIS		
No	1	
Yes	0.87 (0.64, 1.89)	0.38

It is notable that CIS might have distinct molecular features compared to papillary urothelial tumors [11, 14]. CIS alone is regarded as high-risk non-MIBC because it is estimated that > 50% of cases will progress to MIBC over time if left untreated [13, 14] Concomitant CIS in patients with papillary NMIBC increases the risk of progression.

Table 6 Cox regression model for OS for the entire cohort using pre-cystectomy data

Variables	OS HR (95% CI)	<i>p</i>
Age	1.00 (0.99, 1.01)	0.23
cT stage		
cT2	1	
cT3-4	1.23 (0.99, 1.51)	0.06
cN stage		
N0	1	
N+	1.54 (1.23, 1.92)	<0.001
Nx	0.91 (0.54, 1.54)	0.73
NAC regimen		
MVAC	1	
ddMVAC	0.66 (0.46, 0.94)	0.02
GC	0.93 (0.67, 1.29)	0.66
Other	0.99 (0.68, 1.43)	0.95
LVI		
No	1	
Yes	1.25 (0.96, 1.65)	0.10
Unknown	1.13 (0.89, 1.45)	0.30
Hydronephrosis		
No	1	
Yes	1.35 (1.07, 1.71)	0.01
Unknown	1.32 (0.98, 1.77)	0.06
CIS		
No	1	
Yes	1.06 (0.83, 1.36)	0.65

If patients with CIS proceed to cystectomy, upstaging can occur in up to 55% of cases compared to 6% of cases without CIS [12]. In patients diagnosed with CIS on initial TURBT, the published literature varies on whether or not CIS itself may predict lower response rates to NAC [14, 15].

In our study, we evaluated the pathologic and clinical outcomes in patients diagnosed with or without CIS on the initial TURBT prior to NAC followed by RC. We found no statistically or clinically significant difference in the pathologic response rates between the two groups when response was defined either as pT0N0 or \leq pT1N0. On Cox regression model for overall survival for the cN0 cohort using clinicopathological data, the presence of CIS was not associated with overall survival. The presence of LVI at TURBT, hydronephrosis and use of chemotherapy regimens other than ddMVAC were associated with shorter overall survival. In our series, we accept that all CIS may not have been captured on initial TURBT, but this has had no bearing on data capture. This reflects higher CIS being diagnosed on final RC specimen analysis. This reflects real-world experiences with CIS reporting on initial TURBT. For the whole cohort, the presence of CIS was not associated with overall survival.

Our study is consistent with two prior smaller reports in the literature. Thomas et al. described the impact of CIS on the pathologic response to NAC, as well as on progression-free survival (PFS) and OS after NAC and RC [13]. Of 137 patients in this single institutional series, 30.7% had CIS prior to treatment. While the pT0N0 rate in the bladder after NAC and RC was lower in patients with pre-treatment CIS (23.2% vs 9.5%), this was predominantly due to pTisN0 and had no negative impact on PFS or OS. Both survival outcomes were similar to patients with pT0N0 disease in this series. Parker et al. reported very similar findings in a series of 189 patients from two centers [15]. There was a lower rate of pT0N0 disease (26.3% vs 10.7%), but no difference in PFS or OS was observed. Some of the patients from this latter series are also captured in our series.

Our study is limited by its retrospective nature. There is variability in the use of NAC regimens, dose schedules and number of cycles administered, as well as surveillance regimens. As a multi-institutional study without central review, it lacks consistency with respect to surgical technique in TURBT and RC, and histopathological reporting. Essentially all patients in this study underwent white light cystoscopy, although this was not captured explicitly (vs blue light). The rate of CIS detection would likely be higher if patients had been evaluated with blue light cystoscopy [16–21], which would have allowed for a more complete analysis of the impact of CIS in the context of NAC. A key strength of the study is its large sample size.

Conclusion

Our multicenter retrospective study demonstrated that concomitant CIS of the bladder at the time of TURBT did not impact pathologic response or overall survival after neoadjuvant or induction chemotherapy and RC in patients with MIBC. These results suggest that concomitant CIS should have no bearing on the treatment decision-making process in patients with MIBC being considered for NAC and RC.

Author contributions NV: protocol/project development, data collection/management, manuscript writing/editing; HZ: data collection/management, data analysis, manuscript writing/editing; JPN: data collection, manuscript writing/editing; RV: data collection, manuscript review; ASF: data collection, manuscript review; LSM: data collection, manuscript review; CPD: data collection, manuscript review; MCM: data collection, manuscript review; LMK: data collection, manuscript review; MSC: data collection, manuscript review; NEJ: data collection, manuscript review; NMG: data collection, manuscript review; JG: data collection, manuscript review; JSM: data collection, manuscript review; EYY: data collection, manuscript review; EX: data collection, manuscript review; NJC: data collection, manuscript review; WK: data collection, manuscript review; MAD: data collection, manuscript review; JAS: data collection, manuscript review; CEE: data collection, manuscript review; SH: data collection, manuscript review; SSS: data collection, manuscript review; JSM: data collection, manuscript

review; JA: data collection, manuscript review; SFS: data collection, manuscript review; JLW: data collection, manuscript review; TMM: data collection, manuscript review; TJB: data collection, manuscript review; SN: data collection, manuscript review; DAB: data collection, manuscript review; YL: data collection, manuscript review; PG: data collection, manuscript review; AJS: data collection, manuscript review; JBS: data collection, manuscript review; BWR: data collection, manuscript review; SD: data collection, manuscript review; PES: data collection, manuscript review; JMH: data collection, manuscript review; AT: manuscript writing/editing; PCB: manuscript writing/editing.

Compliance with ethical standards

Conflicts of interest The authors declare that they have no conflict of interest.

Research involving human participants and animals For this type of study formal consent is not required. This article does not contain any studies with animals performed by any of the authors.

Informed consent Informed consent was obtained from all individual participants included in the study where applicable.

References

- Grossman HB, Natale RB, Tangen CM, Speights VO, Vogelzang NJ, Trump DL, deVere White RW, Sarosdy MF, Wood DP Jr, Raghavan D, Crawford ED (2003) Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. *N Engl J Med* 349(9):859–866 **PMID: 12944571**
- Zargar H, Espiritu PN, Fairey AS, Zargar H, Espiritu PN, Fairey AS, Mertens LS, Dinney CP, Mir MC, Krabbe LM, Cookson MS, Jacobsen NE, Gandhi NM, Griffin J, Montgomery JS, Vasdev N, Yu EY, Youssef D, Xylinas E, Campain NJ, Kassouf W, Dall’Era MA, Seah JA, Ercole CE, Horenblas S, Sridhar SS, McGrath JS, Aning J, Shariat SF, Wright JL, Thorpe AC, Morgan TM, Holzbeierlein JM, Bivalacqua TJ, North S, Barocas DA, Lotan Y, Garcia JA, Stephenson AJ, Shah JB, van Rhijn BW, Daneshmand S, Spiess PE, Black PC et al (2015) Multicenter assessment of neoadjuvant chemotherapy for muscle-invasive bladder cancer. *Eur Urol* 67(2):241–249 **PMID: 25257030**
- Zargar H, Zargar-Shoshtari K, Lotan Y, Shah JB, van Rhijn BW, Daneshmand S, Spiess PE, Black P, Collaborators (2016) Final Pathological Stage after Neoadjuvant Chemotherapy and Radical Cystectomy for Bladder Cancer-Does pT0 Predict Better Survival than pTa/Tis/T1? *J Urol* 195(4 Pt 1):886–893 **PMID: 26521718**
- Weight CJ, Garcia JA, Hansel DE, Fergany AF, Campbell SC, Gong MC, Jones JS, Klein EA, Dreicer R, Stephenson AJ (2009) Lack of pathologic down-staging with neoadjuvant chemotherapy for muscle-invasive urothelial carcinoma of the bladder: a contemporary series. *Cancer* 115(4):792–799 **PMID: 19127557**
- Van Allen EM, Mouw KW, Kim P, Iyer G, Wagle N, Al-Ahmadie H, Zhu C, Ostrovskaya I, Kryukov GV, O’Connor KW, Sfakianos J, Garcia-Grossman I, Kim J, Guancial EA, Bambury R, Bahl S, Gupta N, Farlow D, Qu A, Signoretti S, Barletta JA, Reuter V, Boehm J, Lawrence M, Getz G, Kantoff P, Bochner BH, Choueiri TK, Bajorin DF, Solit DB, Gabriel S, D’Andrea A, Garraway LA, Rosenberg JE (2014) Somatic ERCC2 mutations correlate with cisplatin sensitivity in muscle-invasive urothelial carcinoma. *Cancer Discov* 4:1140–1153 **PMID: 25096233**

6. Plimack ER, Dunbrack RL, Brennan TA, Andrade MD, Zhou Y, Serebriiskii IG, Slifker M, Alpaugh K, Dulaimi E, Palma N, Hoffman-Censits J, Bilusic M, Wong YN, Kutikov A, Viterbo R, Greenberg RE, Chen DY, Lallas CD, Trabulsi EJ, Yelensky R, McConkey DJ, Miller VA, Golemis EA, Ross EA et al (2015) Defects in DNA repair genes predict response to neoadjuvant cisplatin-based chemotherapy in muscle-invasive bladder cancer. *Eur Urol* 68:959–967 **PMID: 26238431**
7. Seiler Plimack ER, Dunbrack RL, Brennan TA, Andrade MD, Zhou Y, Serebriiskii IG, Slifker M, Alpaugh K, Dulaimi E, Palma N, Hoffman-Censits J, Bilusic M, Wong YN, Kutikov A, Viterbo R, Greenberg RE, Chen DY, Lallas CD, Trabulsi EJ, Yelensky R, McConkey DJ, Miller VA, Golemis EA, Ross EA (2015) Impact of molecular subtypes in muscle-invasive bladder cancer on predicting response and survival after neoadjuvant chemotherapy. *Eur Urol* 68(6):959–967 **PMID: 26238431**
8. Liu D, Plimack ER, Hoffman-Censits J, Garraway LA, Bellmunt J, Van Allen E, Rosenberg JE (2016) Clinical validation of chemotherapy response biomarker ERCC2 in muscle-invasive urothelial bladder carcinoma. *JAMA Oncol* 2:1094–1096 **PMID: 27310333**
9. Choi W, Porten S, Kim S, Willis D, Plimack ER, Hoffman-Censits J, Roth B, Cheng T, Tran M, Lee IL, Melquist J, Bondaruk J, Majewski T, Zhang S, Pretzsch S, Baggerly K, Siefker-Radtke A, Czerniak B, Dinney CP, McConkey DJ (2014) Identification of distinct basal and luminal subtypes of muscle-invasive bladder cancer with different sensitivities to frontline chemotherapy. *Cancer Cell* 25(2):152–165 **PMID: 24525232**
10. Dinney CP, Hansel D, McConkey D, Shipley W, Hagan M, Dreicer R, Lerner S, Czerniak B, Waldman F, Groshen S, True LD, Petricoin E, Theodorescu D, Hruszkewycz A, Bajorin D (2014) Novel neoadjuvant therapy paradigms for bladder cancer: results from the national cancer center institute forum. *Urol Oncol* 32(8):1108–1115
11. Masood S, Sriprasad S, Palmer JH, Mufti GR (2004) T1G3 bladder cancer—Indications for early cystectomy. *Int Urol Nephrol* 36(1):41–44 **Int Urol Nephrol. 2004;36(1):41-4. PMID: 15338671**
12. Hermans TJN, Voskuilen CS, van der Heijden MS, Schmitz-Dräger BJ, Kassouf W, Seiler R, Kamat AM, Grivas P, Kiltie AE, Black PC, van Rhijn BWG (2017) Neoadjuvant treatment for muscle-invasive bladder cancer: The past, the present, and the future. *Urol Oncol*. <https://doi.org/10.1016/j.urolonc.2017.10.014>
13. Chade DC, Chade DC, Shariat SF, Godoy G, Savage CJ, Cronin AM, Bochner BH, Donat SM, Herr HW, Dalbagni G (2010) Clinical outcomes of primary bladder carcinoma in situ in a contemporary series. *J Urol* 184(1):74–80 **PMID: 20546806**
14. Thomas DE, Kaimakliotis HZ, Rice KR, Pereira JA, Johnston P, Moore ML, Reed A, Cregar DM, Franklin C, Loman RL, Koch MO, Bihle R, Foster RS, Masterson TA, Gardner TA, Sundaram CP, Powell CR, Beck SDW, Grignon DJ, Cheng L, Albany C, Hahn NM (2017) Prognostic effect of carcinoma in situ in muscle-invasive urothelial carcinoma patients receiving neoadjuvant chemotherapy. *Clin Genitourin Cancer* 15(4):479–486 **PMID: 28040424**
15. Parker WP, Ho PL, Melquist JJ, Parker WP, Ho PL, Melquist JJ, Scott K, Holzbeierlein JM, Lopez-Corona E, Kamat AM, Lee EK et al (2015) The effect of concomitant carcinoma in situ on neoadjuvant chemotherapy for urothelial cell carcinoma of the bladder: inferior pathological outcomes but no effect on survival. *J Urol* 193:1494–1499 **PMID: 25451834**
16. Choi W, Ochoa A, McConkey DJ, Aine M, Höglund M, Kim WY, Real FX, Kiltie AE, Milsom I, Dyrskjöt L, Lerner SP, Choi W, Ochoa A, McConkey DJ, Aine M, Höglund M, Kim WY, Real FX, Kiltie AE, Milsom I, Dyrskjöt L, Lerner SP (2017) Genetic alterations in the molecular subtypes of bladder cancer: illustration in the cancer genome atlas dataset. *Eur Urol* 72(3):354–365 **PMID: 28365159**
17. Knowles MA, Hurst CD (2015) Molecular biology of bladder cancer: new insights into pathogenesis and clinical diversity. *Nat Rev Cancer* 15(1):25–41. <https://doi.org/10.1038/nrc3817> **PMID: 25533674**
18. Dinney CP, McConkey DJ, Millikan RE, Wu X, Bar-Eli M, Adam L, Kamat AM, Siefker-Radtke AO, Tuziak T, Sabichi AL, Grossman HB, Benedict WF, Czerniak B (2004) Focus on bladder cancer. *Cancer Cell* 6:111–116 **PMID: 15324694**
19. Takayanagi A, Masumori N, Takahashi A, Takagi Y, Tsukamoto T (2012) Upper urinary tract recurrence after radical cystectomy for bladder cancer: incidence and risk factors. *Int J Urol* 19(3):229–233. <https://doi.org/10.1111/j.1442-2042.2011.02916.x> **Epub 2011 Nov 28 PMID: 22121922**
20. Volkmer BG, Schnoeller T, Kuefer R, Gust K, Finter F, Hautmann RE (2009) Upper urinary tract recurrence after radical cystectomy for bladder cancer—who is at risk? *J Urol* 182(6):2632–2637 **PMID: 19836794**
21. Kukreja JB, Porten S, Golla V, Ho PL, Noguera-Gonzalez G, Navai N, Kamat AM, Dinney CPN, Shah JB (2017) Absence of tumor on repeat transurethral resection of bladder tumor does not predict final Pathologic T0 stage in bladder cancer treated with radical cystectomy. *Eur Urol Focus*. <https://doi.org/10.1016/j.euf.2016.12.005>

Affiliations

N. Vasdev^{1,2,3} · H. Zargar^{4,5,6} · J. P. Noël^{1,2} · R. Veeratterapillay³ · A. S. Fahey^{8,13} · L. S. Mertens⁹ · C. P. Dinney¹⁰ · M. C. Mir^{4,5} · L. M. Krabbe¹¹ · M. S. Cookson¹² · N. E. Jacobsen¹³ · N. M. Gandhi¹⁴ · J. Griffin¹⁵ · J. S. Montgomery¹⁶ · E. Y. Yu¹⁷ · E. Xylinas¹⁸ · N. J. Campain²⁰ · W. Kassouf²¹ · M. A. Dall'Era²² · J. A. Seah²³ · C. E. Ercole^{4,5} · S. Horenblas⁹ · S. S. Sridhar²³ · J. S. McGrath²⁰ · J. Aning^{3,20} · S. F. Shariat^{18,19} · J. L. Wright¹⁷ · T. M. Morgan¹⁶ · T. J. Bivalacqua¹⁴ · S. North²⁴ · D. A. Barocas²⁵ · Y. Lotan¹¹ · P. Grivas¹⁷ · A. J. Stephenson^{4,5} · J. B. Shah¹⁰ · B. W. van Rhijn⁹ · S. Daneshmand⁸ · P. E. Spiess⁷ · J. M. Holzbeierlein¹⁵ · A. Thorpe³ · P. C. Black⁶

¹ Department of Urology, Hertfordshire and Bedfordshire Urological Cancer Centre, Lister Hospital, Stevenage SG1 4AB, UK

² School of Life and Medical Sciences, University of Hertfordshire, Hatfield, UK

³ Department of Urology, Freeman Hospital, Newcastle Upon Tyne, UK

⁴ Department of Urology, Royal Melbourne Hospital, Melbourne, VIC, Australia

- 5 Department of Surgery, University of Melbourne, Melbourne, VIC, Australia
- 6 Department of Urologic Sciences, University of British Columbia, Vancouver, BC, Canada
- 7 Department of Genitourinary Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA
- 8 USC/Norris Comprehensive Cancer Center, Institute of Urology, University of Southern California, Los Angeles, CA, USA
- 9 Department of Urology, The Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands
- 10 Department of Urology, MD Anderson Cancer Center, Houston, TX, USA
- 11 Department of Urology, University of Texas Southwestern Medical Center, Dallas, TX, USA
- 12 Department of Urology, University of Oklahoma College of Medicine, Oklahoma City, OK, USA
- 13 University of Alberta, Edmonton, AB, Canada
- 14 Department of Urology, The Johns Hopkins School of Medicine, The James Buchanan Brady Urological Institute, Baltimore, MD, USA
- 15 Department of Urology, Medical Center, University of Kansas, Kansas City, KS, USA
- 16 Department of Urology, University of Michigan Health System, Ann Arbor, MI, USA
- 17 Division of Oncology, Department of Medicine, University of Washington School of Medicine and Fred Hutchinson Cancer Research Center, Seattle, WA, USA
- 18 Department of Urology, Weill Cornell Medical College, Presbyterian Hospital, New York, NY, USA
- 19 Department of Urology, Vienna General Hospital, Medical University of Vienna, Vienna, Austria
- 20 Department of Surgery, Exeter Surgical Health Services Research Unit, Royal Devon and Exeter NHS Trust, Exeter, UK
- 21 (Division of Urology) Department of Surgery, McGill University Health Center, Montreal, QC, Canada
- 22 Department of Urology, Davis Medical Center, University of California at Davis, Sacramento, CA, USA
- 23 Princess Margaret Cancer Center, Toronto, ON, Canada
- 24 Cross Cancer Institute, Edmonton, AB, Canada
- 25 Department of Urologic Surgery, Vanderbilt University Medical Center, Nashville, TN, USA